Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043225 | 0.93 | CD274 (0.34) | CD274PDCD1KDM4EMAPTRAB9A | |
| SCHEMBL4042264 | 0.85 | MAPT (0.35) | CD274PDCD1ALDH1A1LMNATP53 | |
| SCHEMBL4043691 | 0.84 | HTR2C (0.32) | CD274PDCD1KDM4EPKMRAB9A | |
| SCHEMBL4042421 | 0.84 | CD274 (0.40) | CD274PDCD1KDM4EALDH1A1TP53 | |
| SCHEMBL4039070 | 0.84 | CYP11B2 (0.39) | EGLN1KDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL4041718 | 0.83 | DRD3 (0.33) | EGLN1 | |
| SCHEMBL4045032 | 0.83 | SMN1; SMN2 (0.36) | CD274KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL4038644 | 0.82 | CA12 (0.40) | CD274PDCD1APPKDM4EALDH1A1 | |
| SCHEMBL4041087 | 0.82 | GAA (0.34) | CD274PDCD1TACR3KDM4EALDH1A1 | |
| SCHEMBL4039153 | 0.81 | FGFR1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | EGLN1 1561/4885CD274 2129/4885PDCD1 3074/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | EGLN1 2163/4885CD274 3053/4885PDCD1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.